CDT Stock Overview
A clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Conduit Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$0.16 |
| Beta | 2.17 |
| 11 Month Change | -27.62% |
| 3 Month Change | -93.85% |
| 1 Year Change | -98.23% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| CDT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -5.4% | -2.8% | 0.2% |
| 1Y | -98.2% | 1.6% | 17.6% |
Return vs Industry: CDT underperformed the US Life Sciences industry which returned 1.5% over the past year.
Return vs Market: CDT underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| CDT volatility | |
|---|---|
| CDT Average Weekly Movement | 17.9% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CDT's share price has been volatile over the past 3 months.
Volatility Over Time: CDT's weekly volatility has decreased from 28% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 7 | Dave Tapolczay | www.conduitpharma.com |
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave’s disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California.
Conduit Pharmaceuticals Inc. Fundamentals Summary
| CDT fundamental statistics | |
|---|---|
| Market cap | US$14.03m |
| Earnings (TTM) | -US$2.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs CDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.42m |
| Earnings | -US$2.41m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -31.7% |
How did CDT perform over the long term?
See historical performance and comparison